Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn:
“Anticoagulation Bridging:
A Clinical Summary Every Practitioner Should Know
Navigating perioperative anticoagulation decisions can be complex — but getting it right is critical for patient safety.
Here are the key clinical pearls from the latest evidence and CHEST 2022 Guidelines:
Why Bridging Therapy Exists?
When initiating warfarin, Protein C drops rapidly while Prothrombin (Factor II) persists for 42–72 hours — creating a transient ‘hypercoagulable‘ window.
Overlapping with UFH or LMWH for a minimum of 5 days bridges this gap safely.
The 5-Day Rule
Stop heparin/LMWH ‘only’ when BOTH conditions are met:
- INR ≥ 2.0
- INR therapeutic for ≥ 24 hours (or two consecutive therapeutic readings)
Routine Perioperative Bridging? Not Recommended.
CHEST 2022 states routine heparin bridging is generally Not recommended for most patients — increased bleeding risk with little to no reduction in thromboembolism.
Reserve it for selected high-risk cases: mechanical heart valves, recent VTE < 3 months, or recent arterial thromboembolism.
DOACs: No Bridging Needed.
Their short half-life and rapid onset make perioperative bridging unnecessary.
Always Watch for HIT.
Platelet drop > 50%, typically 5–10 days post-exposure? Suspect Heparin-Induced Thrombocytopenia.
Stop all heparin immediately and switch to a non-heparin anticoagulant (Argatroban, Fondaparinux, or Bivalirudin).
Reversal When It Matters.
- UFH reversal with Protamine Sulfate
- Life-threatening warfarin bleeding reversal with 4-Factor PCC and IV Vitamin K (faster and more sustained than FFP)
Sound anticoagulation management is where pharmacology, clinical judgment, and patient safety converge.
These principles save lives when applied correctly.
What aspect of anticoagulation bridging do you find most challenging in clinical practice? ”
Stay updated with Hemostasis Today.
-
Jul 26, 2026, 01:35Moustafa Abdou: Ehlers-Danlos Syndrome – Why Collagen Matters for Hemostasis
-
Jul 26, 2026, 01:25Vrisha Shah: Exploring Transgenic Mouse Models for Pregnancy Outcomes at ISTH 2026
-
Jul 26, 2026, 01:06Christine Bork: Why Misinformation Around a Single Vitamin Postpartum is Putting Babies at Risk
-
Jul 26, 2026, 00:44A Significant Step Forward For People With Bleeding Disorders In The Dominican Republic – WFH
-
Jul 25, 2026, 18:00The Evolving Landscape of Factor Replacement Therapy – EAHAD
-
Jul 25, 2026, 17:43Heghine Khachatryan: Advancing Care for Women and Girls With Hemophilia
-
Jul 25, 2026, 17:00Revathy R Menon: A Memorable Milestone at the 39th ISBT Congress
-
Jul 25, 2026, 16:19Nicola Potere: From Scientific Exchange to Global Collaboration at ISTH 2026
-
Jul 25, 2026, 12:11Salma Abosabie: Honored to Have an Oral Presentation on Thromboinflammation at the ISTH 2026